RESUMEN
A 2 mo old domestic shorthair kitten was presented for acute respiratory distress and severe ambulatory difficulties. Thoracic radiography revealed hyperinflation of the left cranial lung lobe and a mass with soft-tissue/gas opacity in the caudal mediastinum, leading to the suspicion of congenital lung lobe emphysema and hiatal hernia. Decreased bone radiopacity and suspected pathological fractures were also present. Complete clinicopathological analyses showed significant ionized hypocalcemia and suspicion of secondary hyperparathyroidism related to an inadequate diet. Lung lobectomy and reduction of the hiatal hernia following a median sternotomy and a cranial laparotomy were performed. IV and oral supplementation of calcium led to a full recovery and improvement in the kitten's walking. A histopathological analysis revealed pulmonary emphysema associated with hypoplastic and irregular bronchial cartilage. Congenital lobar emphysema is a rare disease in both humans and animals. This is the first veterinary report describing a kitten affected by congenital lobar emphysema combined with a hiatal hernia and additionally complicated by secondary nutritional hyperparathyroidism with a good long-term outcome.
Asunto(s)
Enfermedades de los Gatos , Hernia Hiatal , Hiperparatiroidismo Secundario , Enfisema Pulmonar , Animales , Gatos , Femenino , Hernia Hiatal/complicaciones , Hernia Hiatal/cirugía , Hernia Hiatal/veterinaria , Hiperparatiroidismo Secundario/complicaciones , Hiperparatiroidismo Secundario/cirugía , Hiperparatiroidismo Secundario/veterinaria , Pulmón/anomalías , Pulmón/patología , Pulmón/cirugía , Enfisema Pulmonar/congénito , Enfisema Pulmonar/cirugía , Enfisema Pulmonar/veterinariaRESUMEN
BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak began in late 2019 and spread rapidly throughout China and then the rest of the world. COVID-19 is a serious respiratory disease and many patients' exhibit varying levels of persistent parenchymal lung damage. However, there is currently a lack of effective rehabilitation treatments for COVID-19 patients with lung damage. Several clinical trials have shown that Liuzijue Qigong (LQG) can enhance the strength of respiratory muscles and overall quality of life. In this study, a meta-analysis approach was used to assess the effects of LQG on the lung function of COVID-19 patients during disease recovery. METHODS: Eight databases will be explored for relevant investigations including China National Knowledge Infrastructure, Wanfang, VIP, China Biology Medicine, EMBASE, PubMed, Web of Science, and the Cochrane Library. All databases will be explored for articles published from inception through July 2021. Data will be extracted independently by 2 researchers according to the eligibility criteria. Finally, RevMan 5.3.0 will be implemented for statistical analyses. RESULTS: The results of this study will show the effects of LQG on the lung function of COVID-19 patients during disease recovery and will be submitted to a peer-reviewed journal for publication. CONCLUSIONS: This study will provide reliable evidence based on the effects of LQG on the lung function of COVID-19 patients during disease recovery. TRIAL REGISTRATION NUMBER: CRD42021268102.
Asunto(s)
COVID-19/terapia , Protocolos Clínicos , Pulmón/anomalías , Qigong/normas , COVID-19/psicología , Humanos , Pulmón/fisiopatología , Metaanálisis como Asunto , Qigong/métodos , Pruebas de Función Respiratoria/métodos , Revisiones Sistemáticas como Asunto , Resultado del TratamientoRESUMEN
Perinatal nicotine exposure can not only lead to lung dysplasia in offspring, but also cause epigenetic changes and induce transgenerational asthma. Previous studies have shown that electro-acupuncture (EA) applied to "Zusanli" (ST 36) can improve the lung morphology and correct abnormal expression of lung development-related protein in perinatal nicotine exposure offspring. However, it is still unclear whether ST 36 has a specific therapeutic effect and how maternal acupuncture can protect the offspring from pulmonary dysplasia. In this study, we compared the different effect of ST 36 and "Fenglong" (ST 40), which belong to the same meridian, in terms of lung pulmonary function and morphology, PPARγ, ß-catenin, GR levels in the lung tissues and CORT in the serum of perinatal nicotine exposure offspring, and explored the mechanism of acupuncture based on the maternal hypothalamus-pituitary-adrenal (HPA) axis. It is shown that EA applied to ST 36 could restore the normal function of maternal HPA axis and alleviate maternal glucocorticoid overexposure in offspring, thereby it can up-regulate the PTHrP/PPARγ and down-regulate the Wnt/ß-catenin signaling pathways, and protects perinatal nicotine exposure-induced pulmonary dysplasia in offspring. Its effect is better than that of ST 40. These results are of great significance in preventing perinatal nicotine exposure-induced pulmonary dysplasia in offspring.
Asunto(s)
Electroacupuntura , Pulmón/anomalías , Exposición Materna , Nicotina/toxicidad , Animales , Femenino , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Pulmón/metabolismo , Pulmón/patología , Pulmón/fisiopatología , Masculino , PPAR gamma/metabolismo , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/metabolismo , Ratas Sprague-Dawley , Transducción de Señal , beta Catenina/metabolismoRESUMEN
INTRODUCTION: The purpose of this study was to evaluate clinical outcomes in children with asymptomatic congenital lung malformations (CLM) who were initially managed nonoperatively. METHODS: An IRB-approved retrospective review was performed on all CLMs at a single tertiary care referral center (Jan 2006-Dec 2016, n=140). Asymptomatic cases that did not undergo elective resection were evaluated for subsequent CLM-related complications based on clinical records and a telephone quality of life survey. RESULTS: Out of 39 (27.9%) who were initially managed nonoperatively, 13 (33%) developed CLM-related symptoms and underwent surgical intervention at a median age of 6.8years (range, 0.7-19.8years). The most common indication for conversion to operative management was pneumonia (78%). Larger lesions, as measured by CT scan, were significantly associated with the need for subsequent surgical intervention (mean maximal diameter, 5.7 vs. 2.9cm; p=0.005). Based on survey data with a median follow up of 3.9years (range, 0.2-13.2years), 17% developed chronic pulmonary symptoms, including cough (11%) and asthma requiring bronchodilators (12%). CONCLUSION: Although these data support nonoperative management as a viable alternative to surgical resection, at least one-third of CLM children eventually develop pneumonia or other pulmonary symptoms. Larger lesions are correlated with an increased risk for eventual surgical resection. LEVEL OF EVIDENCE: Level IV.
Asunto(s)
Tratamiento Conservador , Enfermedades Pulmonares/congénito , Enfermedades Pulmonares/terapia , Pulmón/anomalías , Anomalías del Sistema Respiratorio/terapia , Adolescente , Adulto , Enfermedades Asintomáticas , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Masculino , Calidad de Vida , Estudios Retrospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
Studies have demonstrated that maternal consumption of a high fat diet (HFD) increases offspring susceptibility to metabolic disease. This study was initiated to identify the mechanistic contribution of oxidative stress on this phenomenon. Two weeks prior to mating, dams were fed either HFD or Control diet with or without supplementation with the anti-oxidant N-acetylcysteine (NAC). Pups born to HFD dams had reduced crown rump length (CRL) at birth and higher neonatal mortality compared to pups from Control dams. Supplementation with NAC normalized CRL in pups from HFD dams, but notably increased mortality. Histological examination of the lungs postnatally and prenatally, revealed normal branching morphogenesis but delayed alveolarization in pups from dams fed HFD+NAC. Discontinuation of NAC at ED17.5 with re-introduction at PD3 improved offspring survival and lung maturation. Additionally, interscapular brown adipose tissue (BAT) was reduced in ED18.5 embryos from HFD dams. These findings suggest that increased mortality in offspring from dams fed HFD+NAC during pregnancy may in part be the result of delayed pulmonary alveolarization and decreased BAT.
Asunto(s)
Acetilcisteína/efectos adversos , Adiposidad , Dieta Alta en Grasa/efectos adversos , Pulmón/anomalías , Efectos Tardíos de la Exposición Prenatal/patología , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Adiposidad/efectos de los fármacos , Animales , Femenino , Pulmón/efectos de los fármacos , Pulmón/crecimiento & desarrollo , Ratones , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamenteRESUMEN
Congenital diaphragmatic hernia (CDH) can induce lung hypoplasia and pulmonary hypertension and is associated with high mortality. The purpose of this study is to examine the efficacy and safety of antenatal Saireito (TJ-114), a traditional Japanese herbal medicine, in a rat CDH model. Sprague-Dawley rats were exposed to an herbicide (nitrofen, 100 mg) on embryonic day 9 (E9) to induce CDH, and antenatal Saireito (2000 mg/kg/day) was orally administered from E10 to E20. On E21, fetuses were delivered. Antenatal Saireito significantly decreased the incidence of CDH (p < 0.01), increased lung volume (p < 0.01), improved alveolarization and pulmonary artery remodeling using histological analysis, and improved respiratory function using gasometric analysis (pH; p < 0.05, and PCO2 ; p < 0.01). In addition, antenatal Saireito significantly decreased endothelin-1 and endothelin receptor A expression in the pulmonary arteries. Taken together, our results demonstrated that antenatal Saireito can improve fetal pulmonary hypoplasia and pulmonary vascular remodeling and, as a result, can improve respiratory function in a rat CDH model. Copyright © 2016 John Wiley & Sons, Ltd.
Asunto(s)
Anomalías Múltiples/etiología , Medicamentos Herbarios Chinos/uso terapéutico , Hernias Diafragmáticas Congénitas/tratamiento farmacológico , Enfermedades Pulmonares/etiología , Pulmón/anomalías , Éteres Fenílicos/efectos adversos , Remodelación Vascular/fisiología , Anomalías Múltiples/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Perros , Medicamentos Herbarios Chinos/administración & dosificación , Femenino , Pulmón/patología , Enfermedades Pulmonares/tratamiento farmacológico , Ratas , Ratas Sprague-DawleyRESUMEN
Infants with congenital diaphragmatic hernia (CDH) fail to adapt at birth because of persistent pulmonary hypertension (PH), a condition characterized by excessive muscularization and abnormal vasoreactivity of pulmonary vessels. Activation of soluble guanylate cyclase by BAY 41-2272 prevents pulmonary vascular remodeling in neonatal rats with hypoxia-induced PH. By analogy, we hypothesized that prenatal administration of BAY 41-2272 would improve features of PH in the rabbit CDH model. Rabbit fetuses with surgically induced CDH at day 23 of gestation were randomized at day 28 for an intratracheal injection of BAY 41-2272 or vehicle. After term delivery (day 31), lung mechanics, right ventricular pressure, and serum NH2-terminal-pro-brain natriuretic peptide (NT-proBNP) levels were measured. After euthanasia, lungs were processed for biological or histological analyses. Compared with untouched fetuses, the surgical creation of CDH reduced the lung-to-body weight ratio, increased mean terminal bronchial density, and impaired lung mechanics. Typical characteristics of PH were found in the hypoplastic lungs, including increased right ventricular pressure, higher serum NT-proBNP levels, thickened adventitial and medial layers of pulmonary arteries, reduced capillary density, and lower levels of endothelial nitric oxide synthase. A single antenatal instillation of BAY 41-2272 reduced mean right ventricular pressure and medial thickness of small resistive arteries in CDH fetuses. Capillary density, endothelial cell proliferation, and transcripts of endothelial nitric oxide synthase increased, whereas airway morphometry, lung growth, and mechanics remained unchanged. These results suggest that pharmacological activation of soluble guanylate cyclase may provide a new approach to the prenatal treatment of PH associated with CDH.
Asunto(s)
Activadores de Enzimas/farmacología , Hernias Diafragmáticas Congénitas/fisiopatología , Hipertensión Pulmonar/tratamiento farmacológico , Pirazoles/farmacología , Piridinas/farmacología , Anomalías Múltiples/tratamiento farmacológico , Animales , Evaluación Preclínica de Medicamentos , Activadores de Enzimas/uso terapéutico , Femenino , Enfermedades Fetales/tratamiento farmacológico , Guanilato Ciclasa/metabolismo , Hernias Diafragmáticas Congénitas/tratamiento farmacológico , Pulmón/anomalías , Pulmón/efectos de los fármacos , Pulmón/patología , Enfermedades Pulmonares/tratamiento farmacológico , Embarazo , Atención Prenatal , Pirazoles/uso terapéutico , Piridinas/uso terapéutico , Conejos , Resultado del TratamientoRESUMEN
El enfisema lobar congénito suele tratarse quirúrgicamente. Actualmente, se recomienda el término de hiperinsuflación lobar congénita, ya que se trata de un tejido pulmonar anatomopatológicamente sano, motivo por el que el manejo conservador puede ser una alternativa válida. Se presentan 4 casos diagnosticados de hiperinsuflación lobar congénita en los que se optó por el tratamiento conservador debido a su estabilidad clínica y en los que la evolución de los mismos ha sido satisfactoria con normalidad radiológica progresiva
Congenital lobar emphysema used to be treated surgically. Congenital lobar hyperinflation is the currently recommended term, as it involves pathologically healthy lung tissue, which is why conservative management may be an option. Four cases of diagnosed congenital lobar hyperinflation are presented in which conservative treatment was chosen due to their clinical stability. Their outcome has been satisfactory with progressively normal radiology
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Enfisema Pulmonar/congénito , Bronquios/anomalías , Anomalías del Sistema Respiratorio , Pulmón/anomalías , Tratamientos Conservadores del Órgano/métodos , Asfixia Neonatal/etiologíaRESUMEN
PURPOSE: Prenatal treatment with retinoic acid (RA) has been reported to stimulate alveologenesis in hypoplastic lungs (HL) in the nitrofen model of congenital diaphragmatic hernia (CDH). Parathyroid hormone-related protein (PTHrP) promotes alveolar maturation by stimulating surfactant production, regulated by PTHrP receptor (PTHrP-R). PTHrP knockout and PTHrP-R null mice both exhibit pulmonary hypoplasia. We have recently reported that nitrofen inhibits PTHrP signaling in the nitrofen-induced HL. Because both PTHrP and PTHrP-R genes have RA-inducible element, we hypothesized that prenatal administration of RA upregulates pulmonary gene expression of PTHrP and PTHrP-R in the nitrofen-induced HL. METHODS: Pregnant rats were exposed to either olive oil or nitrofen on day 9 of gestation (D9). RA was given on days D18, D19 and D20. Fetal lungs were obtained on D21 and divided into four groups: control, control + RA, nitrofen, nitrofen + RA. RT-PCR and Immunohistochemistry were performed to investigate the pulmonary PTHrP and PTHrP-R gene and protein expression in each group, respectively. RESULTS: The pulmonary gene expression levels of PTHrP and PTHrP-R were significantly increased in nitrofen + RA group compared to nitrofen group (p < 0.05). Immunoreactivity of PTHrP and PTHrP-R was also remarkably increased in nitrofen + RA group compared to nitrofen group. CONCLUSIONS: Upregulation of PTHrP and PTHrP-R genes after prenatal treatment with RA in the nitrofen-induced HL suggests that RA may have a therapeutic potential in reverting lung hypoplasia in CDH, by stimulating surfactant production and alveolar maturation.
Asunto(s)
Enfermedades Pulmonares/embriología , Pulmón/anomalías , Pulmón/embriología , Proteína Relacionada con la Hormona Paratiroidea/metabolismo , Transducción de Señal/efectos de los fármacos , Tretinoina/farmacología , Análisis de Varianza , Animales , Modelos Animales de Enfermedad , Femenino , Pulmón/efectos de los fármacos , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/metabolismo , Aceite de Oliva , Proteína Relacionada con la Hormona Paratiroidea/efectos de los fármacos , Éteres Fenílicos , Aceites de Plantas , Embarazo , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Pulmonary hypoplasia and persistent pulmonary hypertension are the most important reasons for the high morbidity and mortality of congenital diaphragmatic hernia (CDH). Despite surgical advances and advances in neonatal intensive care, the mortality still remains high. Then the research on how to improve prenatal fetal lung growth has become a focus. Some researches involved in fetal surgery, tracheal occlusion, prenatal use of corticosteroids etc., have been carried out in CDH animal models and humans. But the results either showed no benefit for the outcome of CDH or were unproved. Tetrandrine is a bisbenzylisoquinoline alkaloid isolated from the root of Stephania tetrandra. It has been used in traditional Chinese medicine for several decades to treat patients with silicosis, asthma and pulmonary hypertension etc. Some researches showed that prenatal tetrandrine administration can improve the lung development in CDH rat models. We hypothesize that prenatal treatment with tetrandrine can reverse the abnormal condition in the lung of newborn with CDH, and thus decrease the mortality.
Asunto(s)
Bencilisoquinolinas/administración & dosificación , Hernias Diafragmáticas Congénitas , Pulmón/efectos de los fármacos , Exposición Materna , Animales , Femenino , Humanos , Recién Nacido , Pulmón/anomalías , EmbarazoRESUMEN
PURPOSE: The aim of this study was to evaluate the effect of the traditional Chinese medicine tetrandrine (Tet) and to determine its possible mechanism on expression of endothelin-1 (ET-1) and epidermal growth factor (EGF) in the lung of a rat model of nitrofen-induced congenital diaphragmatic hernia (CDH). METHODS: A single oral dose (115 mg/kg) of nitrofen on day 9.5 of pregnancy was maternally administered to induce CDH. Pregnant rats were divided into 4 groups on day 18.5: control (n = 5), CDH (n = 5), CDH+dexamethasone (Dex) (n = 5), and CDH+Tet (n = 5). All fetuses were delivered by cesarean delivery on day 21.5. Accordingly, there were 4 groups of fetuses: control (n = 38), CDH (n = 25), CDH+Dex (n = 21), and CDH+Tet (n = 22). Lung tissue weight (LW) and body weight (BW) of each fetus were recorded, lung histologic evaluations and ET-1 and EGF immunohistochemistry staining were performed, and image analysis was performed after lung processing. RESULTS: Five female rats in the control group produced 38 fetuses without CDH. CDH was observed in 68 of the 128 rat fetuses (53.1%) among the other 3 groups. The LW/BW ratio of the CDH group was significantly lower than those of the Dex and EGF groups (P < .05). The lungs of fetuses with CDH showed marked abnormal structure such as pulmonary hypoplasia and vascular remodeling, in contrast to improved pulmonary structure in lungs of fetuses in the CDH+Dex and CDH+Tet groups. Statistical differences in morphologic parameters (radial alveolar counts, percentage of alveoli, percentage of medial wall thickness, and vascular volume) were found (P < .05). The immunoreactivity of EGF and ET-1 in the CDH group was markedly stronger than that in the control, CDH+Dex, and CDH+Tet groups (P < .01). In addition, EGF and ET-1 expression in the CDH+Dex and CDH+Tet groups was stronger than that in the control group (P < .05). There was no difference in lung EGF and ET-1 immunoreactivity between CDH+Dex and CDH+Tet groups (P > .05). CONCLUSION: Antenatal treatment with Tet may improve lung growth and vascular remodeling, and its mechanism seems to be involved in decreasing EGF and ET-1 expression. Tet administered maternally may be a hopeful new therapeutic option in the treatment of CDH and may be effective in helping to avoid the side effects of Dex.
Asunto(s)
Anomalías Inducidas por Medicamentos/prevención & control , Alcaloides/uso terapéutico , Bencilisoquinolinas/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Endotelina-1/análisis , Factor de Crecimiento Epidérmico/análisis , Madurez de los Órganos Fetales/efectos de los fármacos , Hernia Diafragmática/tratamiento farmacológico , Pulmón/efectos de los fármacos , Anomalías Inducidas por Medicamentos/etiología , Alcaloides/administración & dosificación , Alcaloides/farmacología , Animales , Bencilisoquinolinas/administración & dosificación , Bencilisoquinolinas/farmacología , Peso al Nacer/efectos de los fármacos , Dexametasona/administración & dosificación , Dexametasona/uso terapéutico , Evaluación Preclínica de Medicamentos , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/farmacología , Femenino , Hernia Diafragmática/inducido químicamente , Pulmón/anomalías , Pulmón/química , Pulmón/embriología , Pulmón/patología , Tamaño de los Órganos/efectos de los fármacos , Éteres Fenílicos/administración & dosificación , Éteres Fenílicos/toxicidad , Embarazo , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/embriología , Distribución Aleatoria , Ratas , Ratas Sprague-DawleyRESUMEN
PURPOSE: The aim of the study was to define the details of the history and clarify the cause for respiratory distress, justify the need for surgical correction and suggest a rational operative technique for patients with lung aplasia. METHODS: Our experience with the management of 9 patients with lung aplasia and 1 patient with lung agenesis in the period from 1985 to 2004 is presented. All 10 patients were referred for respiratory distress. A detailed study of clinical symptoms and the data from X-ray, computed tomography (CT), tracheobronchoscopy and digital subtraction angiography (DSA) suggested that all patients had different degrees of mediastinal shift and heart rotation, tracheal kinking and compression of the aortic arch and innominate artery or emphysema of a single lung. Two of the patients required operation. RESULTS: We performed ipsilateral cephalad translocation of the diaphragm which resulted in complete recovery from respiratory distress and a significant improvement in tolerance of physical exercise in both patients. The good results in these patients were followed up for 8 and 2 years, respectively. CONCLUSIONS: We suggest that ipsilateral translocation of the diaphragm could be a useful alternative to unsuccessful symptomatic treatment in patients with lung aplasia.
Asunto(s)
Enfermedades Pulmonares , Pulmón/anomalías , Neumonectomía/métodos , Angiografía de Substracción Digital , Broncografía , Broncoscopía , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Humanos , Lactante , Enfermedades Pulmonares/congénito , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/cirugía , Masculino , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Retinoids are a group of molecules derived from vitamin A, which play an important role in lung development. Within the cell, retinol can either be oxidized to retinal or esterified to retinyl esters by lecithin : retinol acyltransferase (LRAT) for storage. Retinal is then oxidized to an active metabolite of vitamin A, retinoic acid (RA) by retinal dehydrogenase (RALDH). RA is the active metabolite of vitamin A. Cyp26 (a1,b1, and c1), which is a member of the cytochrome P450 family, acts by reducing the activity of RA. Cyp26 type b1 is the predominant subtype expressed in the murine lung. Several studies have suggested that nitrofen may interfere with the retinoid pathway resulting in congenital diaphragmatic hernia (CDH) and pulmonary hypoplasia. Recently, it was reported that nitrofen may act by inhibiting RALDH2. The aim of this study was to examine the pulmonary expression of Cyp26b1, LRAT, and RALDH2, the key enzymes involved in the synthesis of RA, in order to understand the mechanisms underlying pulmonary hypoplasia in the nitrofen CDH model. Pregnant rats were exposed to either olive oil or 100 mg of nitrofen on day 9 of gestation (D9). Fetal lungs were harvested at D15, D17, D19, and D21. D17, D19, and D21 lungs were divided into three groups: control, nitrofen without CDH and nitrofen with CDH, whereas D15 lungs were divided into only two groups; control and nitrofen as the diaphragm is not fully formed yet at this stage. Real- time PCR was performed to evaluate the relative level of Cyp26b1, LRAT, and RALDH2 expression in the lung. Relative levels of Cyp26b1 mRNA were significantly decreased in the lungs of nitrofen with CDH (D17;0.19 +/- 0.09, D19;0.70 +/- 0.20, D21;0.40 +/- 0.36) and nitrofen without CDH (D17;0.14 +/- 0.06, D19;0.54 +/- 0.42, D21;0.51 +/- 0.56) compared to controls (D17;0.35 +/- 0.16, D19;1.15 +/- 0.48, D21;1.28 +/- 0.78) (P < 0.05). LRAT expression was also significantly decreased in nitrofen with CDH (D17; 19.3 +/- 7.8, D19; 4.3 +/- 1.1, D21; 3.3 +/- 1.6) and nitrofen without CDH (D17; 21.2 +/- 11.1, D19; 4.5 +/- 3.6, D21; 4.1 +/- 1.6) compared to controls (D17; 153.7 +/- 29.8, D19; 26.8 +/- 16.8 D21; 10.1 +/- 3.8) (P < 0.05). There was no significant difference in the relative levels of Cyp26b1 and LRAT between nitrofen with CDH and nitrofen without CDH. There were no significant differences in RALDH2 expression among the groups at any stages. Down-regulation of Cryp26b1 and LRAT demonstrates that RA content is decreased in nitrofen induced hypoplastic lungs compared to controls. The finding that RALDH2 expression in the hypoplastic lung is not altered suggests that nitrofen may act by interfering with the retinoid metabolism during the early stage of the retinoid signaling pathway.
Asunto(s)
Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Herbicidas/toxicidad , Hernia Diafragmática/inducido químicamente , Enfermedades Pulmonares/inducido químicamente , Pulmón/anomalías , Éteres Fenílicos/toxicidad , Tretinoina/metabolismo , Aciltransferasas/metabolismo , Animales , Sistema Enzimático del Citocromo P-450/metabolismo , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Femenino , Herbicidas/administración & dosificación , Hernia Diafragmática/enzimología , Hernias Diafragmáticas Congénitas , Pulmón/efectos de los fármacos , Pulmón/enzimología , Enfermedades Pulmonares/enzimología , Enfermedades Pulmonares/fisiopatología , Aceite de Oliva , Éteres Fenílicos/administración & dosificación , Aceites de Plantas/administración & dosificación , Embarazo , Efectos Tardíos de la Exposición Prenatal , Ratas , Ratas Sprague-Dawley , Retinal-Deshidrogenasa/metabolismo , Ácido Retinoico 4-Hidroxilasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodosRESUMEN
Patients with beta-thalassemia often present with a restrictive pattern at pulmonary function tests (PFTs) due to several pathogenetic factors. However, the long-term evolution is unknown. We performed a longitudinal study of pulmonary function in asymptomatic, non-smoking patients with beta-thalassemia major and intermedia. We looked for temporal changes in lung function and characteristics that would predict the development of PFT abnormalities. In 1996, 18 patients with major beta-thalassemia (9 males and 9 females; age range: 18-35 years) and 11 patients with intermediate beta-thalassemia (5 males and 6 females; age range: 25-51 years) underwent clinical assessment and PFT, including body plethysmography and gas transfer study (carbon monoxide diffusion capacity, DL(CO)). Patients were reassessed in 2003. An echocardiographic evaluation was also obtained to exclude pulmonary hypertension. In 55.5% of major and 45.4% of intermediate beta-thalassemia patients, a restrictive pattern was found in 1996; in 2003 only 38.8 and 27.2% of patients, respectively, exhibited total lung capacities below the predicted values. DL(CO) was unchanged in both groups of patients, being reduced in 5 thalassemia major patients and within the normal range in intermediate patients. We conclude that asymptomatic patients with beta-thalassemia have a high prevalence of PFT abnormalities, but without significant increases over time. An improvement may be observed when good control of the iron balance is reached with optimal chelation therapy.
Asunto(s)
Pulmón/fisiopatología , Talasemia beta/fisiopatología , Adolescente , Adulto , Terapia por Quelación , Femenino , Humanos , Hierro/metabolismo , Estudios Longitudinales , Pulmón/anomalías , Pulmón/metabolismo , Masculino , Persona de Mediana Edad , Pletismografía Total , Prevalencia , Intercambio Gaseoso Pulmonar , Talasemia beta/metabolismo , Talasemia beta/terapiaRESUMEN
Swyer-James-MacLeod Syndrome (SJMS) is considered to be a relatively uncommon and complex disease characterized by roentgenographic hyperlucency of one lung, lobe, or part of a lobe, due the pulmonary vascular structure and alveolar overdistension. It is sometimes associated with bronchiectasis. This syndrome seems to be an acquired disease that develops after viral bronchiolitis and/or viral pneumonia in early childhood. Microscopically, there is evidence of patchy bronchitis and bronchiolitis.SJMS is usually asymptomatic and discovered accidentally by chest radiography in a child with respiratory symptoms and should be differentiated from other causes of unilateral hyperlucency on chest radiography, such as those related to congenital bronchial and/or vascular abnormalities. Treatment includes early control of lung infections, as well as influenza and pneumococcal vaccination. Few reports of this syndrome in children have been published. We describe the case of a 12-year-old boy with unilateral hyperlucency of the lung and respiratory symptoms of acute pneumonia and discuss the main diagnostic features of this syndrome.
Asunto(s)
Bronconeumonía/complicaciones , Pulmón Hiperluminoso/diagnóstico , Enfermedad Aguda , Amoxicilina/uso terapéutico , Bronquiolitis Obliterante/complicaciones , Bronconeumonía/diagnóstico , Bronconeumonía/tratamiento farmacológico , Niño , Anomalías Congénitas/diagnóstico , Diagnóstico Diferencial , Humanos , Vacunas contra la Influenza/administración & dosificación , Pulmón/anomalías , Pulmón Hiperluminoso/diagnóstico por imagen , Pulmón Hiperluminoso/etiología , Masculino , Vacunas Neumococicas/administración & dosificación , Arteria Pulmonar/anomalías , Cintigrafía , Tomografía Computarizada Espiral , Relación Ventilacion-PerfusiónRESUMEN
BACKGROUND/PURPOSE: This study examined whether an injectable hydrogel could buttress the balloon used in fetal tracheal occlusion, thus preventing its displacement. METHODS: Fetal lambs (n = 11) underwent tracheal occlusion through local delivery of a detachable silicone balloon and were divided in 2 groups: group I had no further manipulations, and group II received an intratracheal injection of a rapidly polymerizing hydrogel, cranially to the balloon. Near term, balloon placement was examined, the lung volume-to-body weight ratio (LV:BW) was determined, and tracheal histology was performed. Statistical analysis was by the Fisher's Exact test, with significance set at P <.05. RESULTS: Complete tracheal occlusion was achieved in all fetuses intraoperatively. The rate of balloon dislodgement was significantly higher in group I (4 of 7, or 57.1%) than in group II (0 of 4). In group II, balloons were recovered in situ with a column of residual hydrogel reinforcing their cephalad position. Animals in which balloon occlusion was maintained had significantly higher LV:BW, with no evidence of tracheal damage. CONCLUSIONS: Intratracheal delivery of a rapidly polymerizing hydrogel cephalad to detachable silicone balloons results in improved fetal tracheal occlusion, with no harmful effects to the trachea. This adjuvant principle may enhance minimally invasive balloon tracheal occlusion for treatment of severe fetal pulmonary hypoplasia.
Asunto(s)
Cateterismo , Enfermedades Fetales/terapia , Hernia Diafragmática/terapia , Hidrogel de Polietilenoglicol-Dimetacrilato/uso terapéutico , Tráquea , Implantes Absorbibles , Animales , Anomalías Congénitas/prevención & control , Falla de Equipo , Femenino , Hernia Diafragmática/embriología , Hidrogel de Polietilenoglicol-Dimetacrilato/química , Histerotomía , Pulmón/anomalías , Pulmón/embriología , Trabajo de Parto Prematuro/etiología , Trabajo de Parto Prematuro/prevención & control , Polímeros , Embarazo , Ovinos/embriología , Tráquea/embriologíaRESUMEN
Surfactant protein D (SP-D) and serum conglutinin are closely related members of the collectin family of host defense lectins. Although normally synthesized at different anatomic sites, both proteins participate in the innate immune response to microbial challenge. To discern the roles of specific domains in the function of SP-D in vivo, a fusion protein (SP-D/Cong(neck+CRD)) consisting of the NH(2)-terminal and collagenous domains of rat SP-D (rSP-D) and the neck and carbohydrate recognition domains (CRDs) of bovine conglutinin (Cong) was expressed in the respiratory epithelium of SP-D gene-targeted (SP-D(-/-)) mice. While SP-D/Cong(neck+CRD) fusion protein did not affect lung morphology and surfactant phospholipid levels in the lungs of wild type mice, the chimeric protein substantially corrected the increased lung phospholipids in SP-D(-/-) mice. The SP-D/Cong(neck+CRD) fusion protein also completely corrected defects in influenza A clearance and inhibited the exaggerated inflammatory response that occurs following viral infection. However, the chimeric protein did not ameliorate the ongoing lung inflammation, enhanced metalloproteinase expression, and alveolar destruction that characterize this model of SP-D deficiency. By contrast, a single arm mutant (RrSP-D(Ser15,20)) partially restored antiviral activity but otherwise failed to rescue the deficient phenotype. Our findings directly implicate the CRDs of both SP-D and conglutinin in host defense in vivo. Our findings also strongly suggest that the molecular mechanisms underlying impaired pulmonary host defense and abnormal lipid metabolism are distinct from those that promote ongoing inflammation and the development of emphysema.
Asunto(s)
Colectinas , Glicoproteínas/genética , Glicoproteínas/fisiología , Pulmón/anomalías , Surfactantes Pulmonares/genética , Surfactantes Pulmonares/fisiología , Seroglobulinas/genética , Seroglobulinas/fisiología , Administración por Inhalación , Animales , Western Blotting , Líquido del Lavado Bronquioalveolar/química , Metabolismo de los Hidratos de Carbono , Bovinos , Citocinas/biosíntesis , ADN Complementario/metabolismo , Enfisema/metabolismo , Ensayo de Inmunoadsorción Enzimática , Vectores Genéticos , Virus de la Influenza A/genética , Macrófagos Alveolares/metabolismo , Ratones , Ratones Transgénicos , Modelos Genéticos , Fosfatidilcolinas/metabolismo , Fosfolípidos/metabolismo , Unión Proteica , Estructura Terciaria de Proteína , Proteína D Asociada a Surfactante Pulmonar , Proteínas Recombinantes de Fusión/metabolismoRESUMEN
PURPOSE: Congenital diaphragmatic hernia (CDH) is associated with thickened pulmonary arteries (PA) contributing to pulmonary hypertension. In the current study, the effects of antenatal glucocorticoids and reversible tracheal occlusion (TO) on PA structure were assessed in a hypoplastic lung model. METHODS: A left-sided CDH was created in fetal lambs at 80 days gestation, TO at 108 days, and release of the occlusion (TR) at 129 days. All were given 1 dose of maternal glucocorticoids at 135 days. At 136 days (term, 145 days), the fetus was delivered by cesarian section. CDH (n = 7), CDH + TO (n = 6), CDH + TO + TR (n = 6), and unoperated twin controls (n = 16) were compared. Outcome measurements were (1) lung growth, represented by lung weight to body weight ratio (LW/BW), (2) lung structural maturation, which is inversely proportional to mean terminal bronchiole density (MTBD), (3) PA medial and adventitial areas (square micrometers), (4) lung capillary load, which is the ratio of vessel surface area (SA) to tissue SA ratio. RESULTS: CDH lungs were hypoplastic with a low LW/BW and high MTBD. The small PAs (<75 microm) of CDH had an increased medial area, indicating increased muscle mass and an increased adventitial area. CDH + TO +/- TR increased LW/BW and achieved normal structural lung maturity with a low MTBD. Only CDH + TO thinned the PA medial area closer to control values. The adventitial area remained thick in CDH +/- TO +/- TR when compared with controls. All 4 groups had similar capillary load. CONCLUSIONS: TO may be especially important for PA remodeling in the latter part of gestation, because TR 1 week before delivery prevents thinning of the small PAs in CDH. The shaping achieved by TO in terms of lung growth, structural maturity, and pulmonary artery medial area thinning may prove beneficial in lessening the severity of the associated pulmonary hypertension in CDH.
Asunto(s)
Antiinflamatorios/uso terapéutico , Oclusión con Balón/métodos , Betametasona/uso terapéutico , Modelos Animales de Enfermedad , Enfermedades Fetales/terapia , Glucocorticoides/uso terapéutico , Hernia Diafragmática/terapia , Hernias Diafragmáticas Congénitas , Pulmón/anomalías , Pulmón/efectos de los fármacos , Síndrome de Circulación Fetal Persistente/terapia , Atención Prenatal/métodos , Arteria Pulmonar/anomalías , Arteria Pulmonar/efectos de los fármacos , Tráquea , Animales , Oclusión con Balón/instrumentación , Terapia Combinada , Evaluación Preclínica de Medicamentos , Enfermedades Fetales/mortalidad , Madurez de los Órganos Fetales , Edad Gestacional , Hernia Diafragmática/mortalidad , Humanos , Recién Nacido , Pulmón/crecimiento & desarrollo , Tamaño de los Órganos , Síndrome de Circulación Fetal Persistente/mortalidad , Arteria Pulmonar/crecimiento & desarrollo , Ovinos , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Conditions leading to chronic pulmonary insufficiency can affect infants and children. These can lead to growth failure and delayed development. Among the most common and severe of these are bronchopulmonary dysplasia (BPD) and cystic fibrosis. In addition to the respiratory consequences of these diseases, there is ample evidence that they lead to decreased growth as a result of decreased energy intake and increased energy expenditure. Furthermore, there is evidence that infants with BPD may also have delayed development, independent of the effects of their prematurity. Enhancing the long-term outlook for these conditions may therefore require consideration of both improved pulmonary management and aggressive nutritional management to limit growth failure and potentially enhance developmental outcome. Specific micronutrient supplementation, such as antioxidant therapy, may also enhance pulmonary and nutritional status.